Avramiotis S. Nikolaos, MD, MSc (@NSAvramiotis) profile picture

Neurology Resident @UniSpitalBasel with an orientation in Stroke Medicine

Basel, Switzerland
Joined February 2022
Photo by Avramiotis S. Nikolaos, MD, MSc (@NSAvramiotis)
Avramiotis S. Nikolaos, MD, MSc retweeted
TECNO trial: Intra-arterial Tenecteplase after incomplete thrombectomy is safe but doesn’t significantly improve reperfusion or outcomes vs standard care. More research needed to refine patient selection and treatment strategies in stroke care. #ESOC2026 #VoiceOfStroke #Stroke
19
1
33
2,978
Avramiotis S. Nikolaos, MD, MSc retweeted
#MondayTip #TRIDENT 💊One pill could change post-ICH care. 🧠Low-dose triple antihypertensive therapy ↓ recurrent stroke by 39% and improved BP control vs standard care ☝️Simpler regimens may beat therapeutic inertia 🔗doi.org/10.1056/nejmoa251504…
1
29
55
3,036
Avramiotis S. Nikolaos, MD, MSc retweeted
New analyses from the OCEANIC-STROKE trial show the FXIa inhibitor asundexian reduces both the risk and severity of recurrent ischemic stroke in patients with non-cardioembolic stroke or high-risk TIA 📊 @ESOstroke #VoiceOfStroke #Stroke #ESOC2026 #ClinicalTrials
1
14
36
1,645
Avramiotis S. Nikolaos, MD, MSc retweeted
HOPE trial at #ESOC2026 🚨 Tailoring systolic BP to recanalisation status after EVT improves 90-day outcomes in acute ischemic stroke. Findings: •mRS 0–2: 60.0% vs 46.7%. •Hemorrhage: 22.3% vs 31.6%. •Mortality: 15% both. •Supports individualised BP post-thrombectomy.
1
25
1
50
3,137
Avramiotis S. Nikolaos, MD, MSc retweeted
🧊 The CHILL-ART trial shows that intra-arterial selective hypothermia during thrombectomy improves 90-day functional independence (54.7% vs 39.8%) without increasing safety risks. There was no increase in haemorrhage or mortality. @ESOstroke #ESOC2026 #StrokeTreatment
1
25
1
49
3,797
Avramiotis S. Nikolaos, MD, MSc retweeted
Presented at #SVIN25: CREST-2: In high-grade asymptomatic carotid stenosis, addition of stenting to medical therapy led to a lower risk of stroke over a 4-year period. Endarterectomy did not lead to a significant benefit. Full results: nej.md/3LK9kst Editorial: Managing Asymptomatic Carotid Stenosis nej.md/482XjG1 @svinsociety
9
324
61
691
399,741
Avramiotis S. Nikolaos, MD, MSc retweeted
CREST-2 is out. I had Gemini make an infographic—no errors!
2
36
2
142
11,224
Avramiotis S. Nikolaos, MD, MSc retweeted
Verdict is out!!!!! #CREST2 RESULTS FAVORING CAS!!! Absolute risk difference = 3.2% (95% Cl, 0.6 to 5.9; P=0.016) Relative risk = 2.13 (95% Cl, 1.15 to 4.39) Happening now at #SVIN25 @svinsociety @MThrombectomy – at Doctor Phillips, FL
1
54
3
172
12,332
Avramiotis S. Nikolaos, MD, MSc retweeted
#STROKE: In a secondary analysis of ARCADIA, randomization to apixaban was associated with a lower risk of recurrent ischemic stroke than aspirin in patients with left ventricular systolic dysfunction. @MitchElkind @hoomankamel @ShadiYaghi2 #AHAJournals ahajrnls.org/42Qu1bM
1
29
3
81
5,156
Avramiotis S. Nikolaos, MD, MSc retweeted
🚨 Keynote Alert at #ESOC2025! GOLDEN BRIDGE II shows AI-driven clinical decision support can improve stroke recurrence rates without safety hazards in acute ischemic stroke care. 📍22 May | Helsinki 👥 21,600+ patients, 77 hospitals #Stroke #AI #ClinicalTrials
3
10
831
Avramiotis S. Nikolaos, MD, MSc retweeted
ESTREL trial at #ESOC2025: Levodopa did not boost motor recovery after stroke, but extensive ESTREL data may pave the way for exciting advances in personalized rehabilitation. The awakening of stroke rehabilitation might just be postponed! #Stroke #Rehab
6
19
1,538
Avramiotis S. Nikolaos, MD, MSc retweeted
#ESOC2025 🧠Covert Brain Infarction ⬆️Increase risk of Stroke ~2x 📈More CBI, more risk ☝️Inform the patient 🚭Treat risk factors @ErasmusMC
6
1
27
1,761
Avramiotis S. Nikolaos, MD, MSc retweeted
Presented at #ESOC2025: Tirofiban, an IV antiplatelet, given as an adjunct to IVT, improved the odds of excellent functional outcome in patients with AIS, at the cost of an increased risk of intracranial bleeding in the ASSET-IT trial #VoiceOfStroke
17
57
3,748
Avramiotis S. Nikolaos, MD, MSc retweeted
New DISTAL Trial sub-analysis: Endovascular therapy boosted chances of saving at least 80% of affected brain tissue in medium distal vessel occlusion stroke. Preservation of ≥80% of at-risk brain tissue significantly improved outcomes. Tissue saved = better recovery #ESOC2025
16
49
2,673
Avramiotis S. Nikolaos, MD, MSc retweeted
#ESOC2025 🏃🏻‍♀️ESCAPE MEVO sub analysis 👉🏻 prognosis by image 🧠 👉🏻EVT <12 hs not > good functional outcome 👉🏻 Good collateral status > benefit 👉🏻 ⏱️<180 min > benefit
1
28
2
71
6,070
Avramiotis S. Nikolaos, MD, MSc retweeted
Presented at #ESOC2025: Among 550 patients with stroke due to large-vessel occlusion who had presented within 4.5 hours after onset, 90-day functional outcomes were better with intravenous tenecteplase before thrombectomy than with thrombectomy alone. Read the full BRIDGE-TNK trial results: nej.md/3GTVKAk @ESOstroke
2
68
5
188
23,392
Avramiotis S. Nikolaos, MD, MSc retweeted
#ESOC2025 | The OPTIMIST trial suggests low-intensity monitoring after IV thrombolysis in mild to moderate stroke can deliver comparable safety & outcomes to standard protocols—while easing ICU strain & improving patient experience 📍4922 patients | 114 hospitals | 8 countries
13
25
1,619
Avramiotis S. Nikolaos, MD, MSc retweeted
BRIDGE TNK trial presented at #ESOC2025 shows superior outcomes with IV Tenecteplase + thrombectomy vs thrombectomy alone in acute LVO stroke within 4.5h 🧠 Functional independence - mRS 0–2 🟦 52.9% with bridging vs 44.1% thrombectomy 🧾 Adjusted RR 1.18 #StrokeTreatment
15
44
1,936
Avramiotis S. Nikolaos, MD, MSc retweeted
#ESOC2025 ✅ASSET-IT: early tirofiban after IVT 👉🏻>mRS 0-1 and 0-2 at 90 day in Tirofiban arm 👉🏻 = sICH and mortality al 90 days
1
20
1
56
3,800
Avramiotis S. Nikolaos, MD, MSc retweeted
🚨Neuroprotective agents in Large Core Strokes 👉🏻 Edaravone + Dexborneol vs usual care 👉🏻 < 14 days of onset ✅ drugs: better functional outcomes at 90 days and trend to lower mortality
17
1
53
3,477